Overview
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
Status:
Completed
Completed
Trial end date:
2016-06-08
2016-06-08
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Zealand Pharma
Criteria
Inclusion Criteria:- Age ≥ 18 years
- ST-segment elevation myocardial infarction
- Acute onset of chest pain of < 12 hours duration
Exclusion Criteria:
- Pregnancy
- Known prior Myocardial Infarction in same area as present STEMI, known hypertrophic or
dilated cardiomyopathy, or prior hospital admission for heart failure
- Contraindication for cardiac MRI
- Inability to understand information or provide informed consent